Next Science (ASX:NXS) Pre-Tax Income : A$-16.29 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Next Science Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Next Science's pretax income for the six months ended in Dec. 2024 was A$-7.49 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was A$-16.29 Mil. Next Science's pretax margin was -40.97%.

During the past 7 years, Next Science's highest Pretax Margin was -46.27%. The lowest was -353.38%. And the median was -106.39%.

Next Science Pre-Tax Income Historical Data

The historical data trend for Next Science's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Pre-Tax Income Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

-15.82

-13.07

-18.80

-24.31

-16.72

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial							-9.03	-12.83	-11.44	-8.80	-7.49

Competitive Comparison of Next Science's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Next Science's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Next Science Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Next Science's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-18.316	+	0.035	+	-0.448	+	0.062	+	1.952
	=	-16.72

Next Science's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-8.2	+	-0.052	+	-0.384	+	-0.036	+	1.183
	=	-7.49

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-16.29 Mil.

Next Science (ASX:NXS) Pre-Tax Income Explanation

Next Science's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-7.489	/	18.28
	=	-40.97%

During the past 7 years, Next Science's highest Pretax Margin was -46.27%. The lowest was -353.38%. And the median was -106.39%.

Next Science Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Next Science's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

Next Science Headlines

No Headlines